BackRecce Pharmaceuticals Overview

Recce Pharmaceuticals Receivables

Latest receivables for RCE.AX: $3.9M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$3.87M
↑ 789.79% YoYΔ $3.44M vs prior year quarter

Peer trimmed avg / median

Loading

Recce Pharmaceuticals Receivables History

Loading

Recce Pharmaceuticals vs. peers: Receivables Comparison

Loading

Recce Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Recce Pharmaceuticals (RCE.AX) FAQ

As of the most recent data (June 2026), RCE.AX shows a receivables of $3.9M. That compares with $440K in the prior-year period — up 789.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RCE.AX's receivables is now $3.9M (was $440K) — a 789.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Recce Pharmaceuticals is outperforming or lagging.

Tracking RCE.AX's receivables over time shows whether Recce Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $3.9M That compares with $440K in the prior-year period — up 789.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Recce Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $3.9M) with ownership activity and broader fundamentals.

Recce Pharmaceuticals's receivables is $3.9M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.